Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 5/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17854893 | 0.92 | CXCR3 (0.61) | CXCR3KCNH2ALDH1A1 | |
| SCHEMBL3735603 | 0.90 | CXCR3 (0.59) | CXCR3KCNH2ALDH1A1POLB | |
| SCHEMBL3741729 | 0.89 | CXCR3 (0.56) | CXCR3KCNH2GRIN2BCCR1POLB | |
| SCHEMBL168793 | 0.89 | CXCR3 (0.60) | CXCR3KCNH2GRIN2BGFEREIF2AK3 | |
| SCHEMBL3736608 | 0.89 | CXCR3 (0.76) | CXCR3KCNH2ALDH1A1POLB | |
| SCHEMBL3742956 | 0.88 | CXCR3 (0.59) | CXCR3KCNH2GRIN2BEIF2AK3CYP3A4 | |
| SCHEMBL115730 | 0.88 | CXCR3 (0.56) | CXCR3KCNH2EIF2AK3ALDH1A1CCR1 | |
| SCHEMBL168743 | 0.87 | CXCR3 (0.58) | CXCR3KCNH2GRIN2BGFEREIF2AK3 | |
| SCHEMBL178025 | 0.87 | CXCR3 (0.58) | CXCR3KCNH2GRIN2BGFEREIF2AK3 | |
| SCHEMBL3728380 | 0.86 | CXCR3 (0.56) | CXCR3KCNH2GRIN2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | Edifice Health, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210040195-A1 | Treatment and Prevention of Cardiovascular Disease | Edifice Health, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040195-A1 | Treatment and Prevention of Cardiovascular Disease | SERPINA6, FABP3, CXCL8 | CXCR3 835/4885KCNH2 3076/4885GRIN2B 4803/4885 |
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | SERPINA6, FABP3, CXCL8 | CXCR3 835/4885KCNH2 3076/4885GRIN2B 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.